Medical institute Albert Einstein College of Medicine, Montefiore Health System and the Fire Department of the City of New York (FDNY) stated on Friday that the COVID-19 pandemic in New York City has caused an increase in out-of-hospital cardiac arrests and deaths.
Published online in JAMA Cardiology, the study found a three-fold increase in out-of-hospital non-traumatic cardiac-arrest cases in March and April 2020 versus same period in 2019. On 6 April 2020, cardiac arrests peaked at 305 cases, an increase of nearly ten fold over the same day one year earlier. The mortality rate for cardiac-arrest cases rose from 75% in 2019 to 90 % during the same period in 2020.
The study used data from the New York City emergency medical services system. The data was analyzed for patients 18 years or older with out-of-hospital cardiac arrest who received EMS resuscitation from 1 March 2020 when the first case of COVID-19 was diagnosed in New York City through 25 April 2020 when EMS call volume had receded to pre-COVID-19 levels, revealed the partnership.
In addition to overwhelming pneumonia and acute respiratory failure, COVID-19 damages the lining of blood vessels, leading to blood clots that can trigger heart attacks even in people with no previous cardiopulmonary diseases, concluded the partnership.
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
Corstasis and U.S. Heart and Vascular partner to advance heart failure care with ENBUMYST
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Merck reports positive Phase 3 results for oral PCSK9 inhibitor enlicitide
Abbott's Navitor TAVI system granted CE Mark for expanded indication
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
FDA lifts clinical hold on Rocket Pharmaceuticals' RP-A501 Phase 2 Danon disease trial
OptiBiotix signs distribution deal with major weight management company
Novartis to present cardiovascular abstracts portfolio data at ESC Congress in Madrid
LivaNova announces commercial launch of Essenz Perfusion System in China
Viatris' generic iron sucrose injection gains US FDA approval
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
US FDA approves Innovent's IND application for IBI3032 oral GLP-1R agonist